Company Filing History:
Years Active: 2005
Title: The Innovative Contributions of Mary Konsolaki
Introduction
Mary Konsolaki is a prominent inventor based in Westfield, NJ (US). She has made significant contributions to the field of genetics and neuroscience, particularly in relation to Alzheimer's Disease. Her work has implications for understanding the genetic factors involved in this debilitating condition.
Latest Patents
Mary Konsolaki holds a patent for "Transgenic Drosophila melanogaster expressing a β42 in the eye." This patent discloses transgenic flies that exhibit altered phenotypes due to the expression of the Abeta and C99 portions of the human APP gene. The use of these flies is aimed at identifying genes and their human homologs that may be involved in Alzheimer's Disease. Additionally, the patent discusses the potential of these human homologs as drug targets for developing therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway. Pharmaceutical compositions comprising substances directed to these genes are also included in her patent.
Career Highlights
Mary Konsolaki is affiliated with Novartis Corporation, where she continues her research and innovation. Her work has garnered attention for its potential to lead to new therapeutic approaches for Alzheimer's Disease. With a focus on genetic research, she has contributed to advancing our understanding of neurodegenerative diseases.
Collaborations
Mary has collaborated with notable colleagues, including Dalia Cohen and Uwe Jochen Dengler. These collaborations have enriched her research and expanded the impact of her work in the scientific community.
Conclusion
Mary Konsolaki's innovative contributions to the field of genetics and her patent on transgenic Drosophila melanogaster highlight her commitment to advancing research on Alzheimer's Disease. Her work not only enhances our understanding of genetic factors but also paves the way for potential therapeutic developments.